Degarelix
Also known as: Camcevi, Degarelix acetate, FE200486, Firmagon, IUPHAR:1173
Source Degarelix at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Degarelix is a synthetic decapeptide GnRH antagonist approved for androgen deprivation therapy (ADT) in men with prostate cancer. Delivered by subcutaneous injection, it rapidly suppresses luteinising hormone and testosterone without the initial surge seen with GnRH agonists. It is used to achieve castration‑level testosterone as part of definitive or palliative treatment strategies.
Mechanism of Action
Degarelix competitively binds to pituitary GnRH receptors, blocking the endogenous hormone’s action. This inhibition prevents the release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), leading to a swift decline in circulating testosterone to castration levels. Because it antagonises the receptor directly, there is no flare‑up of testosterone that can occur with agonist therapy.
What the Research Shows
The PRONOUNCE randomised trial compared degarelix with the GnRH agonist leuprolide in men with prostate cancer and pre‑existing atherosclerotic cardiovascular disease. Over 12 months, major adverse cardiovascular events occurred in 5.5% of degarelix‑treated patients and 4.1% of leuprolide‑treated patients (hazard ratio 1.28, 95% CI 0.59‑2.79), a non‑significant difference. The trial stopped early because of slower enrollment and fewer events than planned, leaving the cardiovascular safety question unresolved. A separate large randomised study (RADICALS‑HD) examined the optimal duration of ADT after prostatectomy but did not focus on degarelix specifically; it compared long‑course versus short‑course ADT and reported clinical outcomes without detailing agent‑specific effects.
Reported Benefits
Degarelix provides rapid and sustained testosterone suppression, avoiding the testosterone surge associated with GnRH agonists. This can be advantageous when an immediate reduction in androgen levels is clinically desired, such as before surgery or in patients at risk of flare‑related complications. Its subcutaneous formulation allows outpatient administration and has been incorporated into guideline‑based ADT regimens for prostate cancer.
Limitations of the Evidence
Evidence on cardiovascular safety is limited; the PRONOUNCE trial was underpowered and did not demonstrate a clear advantage or disadvantage versus leuprolide. Data on the optimal duration of degarelix‑based ADT are lacking, as the RADICALS‑HD trial did not isolate this agent. Long‑term comparative effectiveness and quality‑of‑life outcomes remain insufficiently characterised.
Safety Considerations
In the PRONOUNCE trial, major adverse cardiovascular events occurred in a small proportion of patients receiving degarelix (5.5%). Overall safety data from the trial did not reveal new safety signals, but the limited sample size means rare adverse events may not be captured. Common adverse effects reported for GnRH antagonists in other studies include injection‑site reactions and hormonal symptoms such as hot flashes, but these were not detailed in the provided abstracts.
How It Is Administered
Degarelix is supplied as a sterile solution for subcutaneous injection. The initial dose is typically given as a loading injection, followed by monthly maintenance injections. Administration is performed in a clinical setting, and the formulation is stored at controlled room temperature until use.
Routes of Administration
Goals & Uses
- Cardiovascular risk reduction vs GnRH agonistsCardiologyModerate
- Prevention of testosterone flareOncology / Hormonal SafetyHigh
- Prostate cancer treatmentOncologyHigh
- Advanced prostate cancer treatmentOncologyHigh
- Neoadjuvant/adjuvant to radiotherapyOncologyModerate
- Rapid testosterone castrationEndocrineHigh
- Androgen deprivation therapy (ADT)EndocrinologyHigh
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Women and pediatric patientsPopulationHigh
- Hypersensitivity to degarelix or excipientsAllergyHigh
Adverse Effects
- Elevated liver enzymes (AST/ALT)HepatotoxicityUncommon
- Injection site reactionsLocalCommon
- Decreased bone mineral densityMusculoskeletalCommon
- Hot flashesEndocrine / VasomotorCommon
- QT/QTc prolongationCardiovascularUncommon
- Weight gainMetabolicCommonIncrease in body weight
- Cardiovascular eventsSystemicRare
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Injection site reactions (pain, erythema, swelling)LocalCommon
Drug Interactions
- Hormonal therapies (e.g., antiandrogens)Moderate
- Class III antiarrhythmics (amiodarone, sotalol)High
- CYP450 substratesLow
- QT-prolonging agents (e.g., antiarrhythmics, antipsychotics)High
- Class IA antiarrhythmics (quinidine, procainamide)High
Population Constraints
- Patients with congenital long QT syndromeCardiovascularRelative
- Pediatric patientsAgeAbsolute
- Patients with severe hepatic impairmentHepaticRelative
- Elderly patients (≥65 years)Age RelatedRelative
- Patients with severe renal impairmentOrgan ImpairmentRelative
- Patients with severe cardiovascular diseaseCardiovascularRelative
Regulatory Status
- European UnionApprovedApproved: Hormone-sensitive prostate cancerMarketing authorization granted.
- United StatesApprovedApproved: Advanced prostate cancerBrand: Firmagon.
- United KingdomApprovedApproved: Prostate cancerAvailable via NHS.
Approved in the US, EU, and UK for treatment of hormone-sensitive prostate cancer; marketed under the brand name Firmagon.
Evidence & Sources
- Journal ArticleModerateLopes RD, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateParker CC, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateKlotz L, et al.2008-01-01T00:00:00.000000Z
- Journal ArticleModerateSecin FP2016-01-01T00:00:00.000000Z
- Journal ArticleModerateDevos G, et al.2023-01-01T00:00:00.000000Z
Frequently Asked Questions
How quickly does degarelix lower testosterone levels?
Degarelix blocks GnRH receptors directly, leading to a rapid fall in luteinising hormone and testosterone within a few days, without the initial testosterone surge seen with agonist drugs.
Is degarelix safer for the heart than leuprolide?
The PRONOUNCE trial found no statistically significant difference in major cardiovascular events between degarelix and leuprolide, but the study was stopped early and was underpowered, so a definitive safety conclusion cannot be drawn.
Can degarelix be used for a short course of ADT after surgery?
The RADICALS‑HD trial compared short versus long ADT courses after prostatectomy, but it did not isolate degarelix; therefore, specific evidence for short‑course degarelix is not available from the cited literature.
How is degarelix administered?
Degarelix is given as a subcutaneous injection, usually an initial loading dose followed by monthly maintenance doses, administered in a healthcare setting.
What are the common side effects?
While the provided abstracts focus on cardiovascular outcomes, other studies of GnRH antagonists report injection‑site discomfort and hormonal symptoms such as hot flashes; these have not been detailed in the cited papers.
What is Degarelix?
Degarelix is a synthetic decapeptide GnRH antagonist approved for androgen deprivation therapy (ADT) in men with prostate cancer. Delivered by subcutaneous injection, it rapidly suppresses luteinising hormone and testosterone without the initial surge seen with GnRH agonists. It is used to achieve castration‑level testosterone as part of definitive or palliative treatment strategies.
What is Degarelix used for?
Degarelix is educationally associated with: Cardiovascular risk reduction vs GnRH agonists, Prevention of testosterone flare, Prostate cancer treatment, Advanced prostate cancer treatment, Neoadjuvant/adjuvant to radiotherapy, Rapid testosterone castration, Androgen deprivation therapy (ADT). Educational only — not medical advice.
How is Degarelix administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Degarelix?
Reported adverse effects include: Elevated liver enzymes (AST/ALT), Injection site reactions, Decreased bone mineral density, Hot flashes, QT/QTc prolongation, Weight gain, Cardiovascular events, Elevated liver enzymes, Injection site reactions (pain, erythema, swelling). This list is not exhaustive — consult a qualified clinician.
Who should avoid Degarelix?
Recorded contraindications: Severe hepatic impairment, Pregnancy, Women and pediatric patients, Hypersensitivity to degarelix or excipients. Consult a qualified clinician before use.